Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $37.20.

Several brokerages have recently weighed in on DNLI. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research note on Monday, December 16th. William Blair reaffirmed an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. The Goldman Sachs Group lowered their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Baird R W upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Finally, Bank of America lowered their target price on Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, March 10th.

Insiders Place Their Bets

In related news, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares in the company, valued at $2,257,778.16. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Carole Ho sold 12,255 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $247,796.10. Following the completion of the transaction, the insider now owns 178,580 shares in the company, valued at $3,610,887.60. This trade represents a 6.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,940 shares of company stock valued at $973,442 over the last ninety days. 7.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC raised its holdings in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock valued at $36,000 after acquiring an additional 1,516 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Denali Therapeutics during the fourth quarter worth about $62,000. Point72 Hong Kong Ltd bought a new position in Denali Therapeutics in the 4th quarter valued at about $65,000. Quest Partners LLC bought a new position in Denali Therapeutics in the 3rd quarter valued at about $73,000. Finally, PNC Financial Services Group Inc. raised its position in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after buying an additional 885 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Trading Down 4.3 %

DNLI stock opened at $14.12 on Wednesday. The stock has a 50-day moving average price of $19.50 and a two-hundred day moving average price of $23.46. Denali Therapeutics has a 1 year low of $14.01 and a 1 year high of $33.33. The stock has a market cap of $2.05 billion, a PE ratio of -5.12 and a beta of 1.46.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, analysts forecast that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.